Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17788668 | 0.79 | KDM4E (0.40) | SMN1; SMN2KDM4ELMNAHSD17B10 | |
| SCHEMBL19087002 | 0.77 | PIN1 (0.39) | PDE2APIN1SMN1; SMN2NOTUMKDM4E | |
| SCHEMBL19077882 | 0.74 | PIN1 (0.47) | PIN1KDM4EHCAR2 | |
| SCHEMBL353311 | 0.74 | PIN1 (0.44) | PIN1KDM4EHCAR2 | |
| SCHEMBL19086997 | 0.72 | KDM4E (0.34) | PDE2AKDM4ELMNAHSD17B10 | |
| SCHEMBL19954222 | 0.67 | KDM4E (0.39) | SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL3027992 | 0.63 | KDM4E (0.37) | PIN1KDM4ELMNAHSD17B10HCAR2 | |
| SCHEMBL570053 | 0.62 | HCAR2 (0.50) | HCAR2 | |
| SCHEMBL24679020 | 0.61 | PDE4B (0.38) | PIN1LMNA | |
| SCHEMBL4185273 | 0.61 | ALOX15 (0.44) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | INCYTE CORPORATION (US) | 2022-06-07 | — | — | US | disclosed |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | INCYTE CORPORATION | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352340-B2 | Pyridine and pyridimine compounds as PI3K-gamma inhibitors | PIK3CG, PIK3CD, PIK3CB | PDE2A 1003/4885PIN1 2325/4885SMN1; SMN2 1910/4885 |
| US-20170190689-A1 | PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS | PIK3CG, PIK3CD, PIK3CB | PDE2A 1003/4885PIN1 2325/4885SMN1; SMN2 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.